PTO/AlA/‘M (12-13)
`Approved for use through 04/3012017. OMB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Underthe Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`
`Application Data Sheet 37 CFR 1.76
`Application Number
`
`
`
`Attorney Docket Number 209658-0001-01-US-518587
`
`
`
`ANTISENSE NUCLEIC ACIDS
`Title of Invention
`
`The application data sheet is part of the provisional or nonprovisional application for which it is being submitted. The following form contains the
`bibliographic data arranged in a format specified by the United States Patent and Trademark Office as outlined in 37 CFR 1.76.
`This document may be completed electronically and submitted to the Office in electronic format using the Electronic Filing System (EFS) or the
`document may be printed and included in a paper filed application.
`
`Secrecy Order 37 CFR 5.2
`
`
`:I Portions or all of the application associated with this Application Data Sheet may fall under a Secrecy Order pursuant to
`
`37 CFR 5.2 (Paper filers only. Applications that fall under Secrecy Order may not be filed electronically.)
`
`Inventor Information:
`
`Inventor
`
`1
`
`Legal Name
`
`
`Prefix Given Name
`Naoki
`
`Middle Name
`
`Family Name
`WATANABE
`
`Suffix
`
`
`
`
`
`
`
`
`
`
`
`
`
`Residence Information (Select One) 0 US Residency @ Non US Residency 0 Active US Military Service
`
`
`
`
`
`
`
`Tsukuba-shi, lbaraki Country of Residence iCity JP
`
`
`Mailing Address of Inventor:
`
`Address 2
`
`
`Address 1
`
`Room 402, Ruvio ll, 21-3, Sakura 1-chome
`
`City
`
`Tsukuba-shi, lbaraki
`
`StatelProvince
`
`305—0003 Country iPostal Code JP
`
`
`
`Inventor
`
`2
`
`
`
`
`
`Legal Name
`
`
`Prefix Given Name
`Youhei
`
`Middle Name
`
`Family Name
`SATOU
`
`Residence Information (Select One) 0 US Residency @ Non US Residency 0 Active US Military Service
`
`Suffix
`
`
`
`
`
`
`City
`
`Tsukuba-shi, lbaraki
`
`Country of Residence I
`
`JP
`
`
`Mailing Address of Inventor:
`
`Address 2
`
`
`Address 1
`
`Room 402, Ruvio ll, 21-3, Sakura 1-chome
`
`City
`Postal Code
`
`Tsukuba-shi, lbaraki
`305—0003
`
`StatelProvince
`JP
`
`3
`Inventor
`
`Legal Name
`
`EFS Web 2.2.11
`
`Sarepta Exhibit 1011, Page 1 of 76
`
`

`

`PTO/AlA/‘M (12-13)
`Approved for use through 04/3012017. OMB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`Application Data Sheet 37 CFR 1.76 Application Number
`
`
`
`Attorney Docket Number 209658-0001-01-US-518587
`
`ANTISENSE NUCLEIC ACIDS
`Title of Invention
`
`
`
`Prefix Given Name
`Shin'lchi
`
`Middle Name
`
`Family Name
`TAKEDA
`
`Suffix
`
`
`
`
`
`
`Residence Information (Select One) 0 US Residency
`6) Non US Residency 0 Active US Military Service
`
`
`
`
`
`
`
`
`City
`
`Kodaira-shi, Tokyo
`
`Country of Residence i
`
`JP
`
`
`
`Mailing Address of Inventor:
`
`Address 2
`1—1, Ogawahigashicho 4—chome
`
`
`Address 1
`
`0/0 National Center of Neurology and Psychiatry
`
`City
`Postal Code
`
`Kodaira-shi, Tokyo
`187—8551
`
`StatelProvince
`JP
`
`Inventor
`4
`Legal Name
`
`Tetsuya
`NAGATA
`
`Residence Information (Select One) 0 US Residency
`(9 Non US Residency 0 Active US Military Service
`
`
`
`Prefix Given Name
`
`Middle Name
`
`Family Name
`
`
`
`City
`
`Kodaira-shi, Tokyo
`
`Country of Residence i
`
`JP
`
`Suffix
`
`
`
`
`Mailing Address of Inventor:
`
`
`
`Address 1 0/0 National Center of Neurology and Psychiatry
`
`1-1, Ogawahigashicho 4-chome
`Address 2
`
`
`I
`I StatelProvince
`I Kodaira—shi, Tokyo
`City
`
`Postal Code
`187-8551
`Country i
`JP
`
`Inventor Information blocks may be
`Inventors Must Be Listed - Additional
`All
`generated within this form by selecting the Add button.
`
`Add
`
`Enter either Customer Number or complete the Correspondence Information section below.
`For further information see 37 CFR 1.33(a).
`
`
`Correspondence Information:
`
`D An Address is being provided for the correspondence Information of this application.
`Customer Number
`055694
`
`
`
`Email Address
`
`DBRIPDocket@dbr.com
`
`EFS Web 2.2.11
`
`Sarepta Exhibit 1011, Page 2 of 76
`
`

`

`PTO/AlA/‘M (12—13)
`Approved for use through 04/3012017. OMB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`
`
`Attorney Docket Number 209658-0001-01-US-518587
`
`Application Number
`
`
`Application Data Sheet 37 CFR 1.76
`
`Title of Invention
`
`ANTISENSE NUCLEIC ACIDS
`
`Application Information:
`
`Title of the Invention
`ANTISENSE NUCLEIC ACIDS
`
`
`Attorney Docket Number 209658-0001-01-US-518587
`Small Entity Status Claimed
`|:|
`
`Application Type
`Nonprovisional
`
`
`
`Subject Matter
`
`Utility
`
`
`
`
`
`
`
`Total Number of Drawing Sheets (if any) Suggested Figure for Publication (if any) 19
`
`
`
`Filing By Reference:
`Only complete this section when filing an application by reference under 35 U.S.C. 1 I I(c) and 37 CFR I.57(a). Do not complete this section if
`application papers including a specification and any drawings are being filed. Any domestic benefit or foreign priority information must be
`provided in the appropriate section(s) below (i.e., “Domestic Benefit/National Stage Information" and “Foreign Priority Information").
`
`For the purposes of a filing date under 37 CFR I.53(b), the description and any drawings of the present application are replaced by this
`reference to the previously filed application, subject to conditions and requirements of37 CFR I.57(a).
`
`Application number of the previously
`
`Filing date (YYYY-MM-DD)
`
`Intellectual Property Authority or Country i
`
`filed application
`
`
`Publication Information:
`
`
`I: Request Early Publication (Fee required at time of Request 37 CFR 1.219)
`
`
`
`|:
`
`I hereby request that the attached application not be published under
`Request Not to PUbiiS h.
`35 U.S.C. 122(b) and certify that the invention disclosed in the attached application has not and will not be the
`subject of an application filed in another country, or under a multilateral international agreement, that requires
`publication at eighteen months after filing.
`
`Representative Information:
`
`Representative information should be provided for all practitioners having a power of attorney in the application. Providing
`this information in the Application Data Sheet does not constitute a power of attorney in the application (see 37 CFR 1.32).
`Either enter Customer Number or complete the Representative Name section below.
`If both sections are completed the customer
`Number will be used for the Representative Information during processing.
`
`
`
`
`
`
`
`0 US Patent Practitioner@ Customer NumberPlease Select One: 0 Limited Recognition (37 CFR 11.9)
`
`
`Customer Number
`055694
`
`
`
`EFS Web 2.2.11
`
`Sarepta Exhibit 1011, Page 3 of 76
`
`

`

`
`
`
`Application Number
`13891520
`
`Continuity Type
`a 371 of international
`
`Prior Application Number
`PCT/JP2011/070318
`
`Filing Date (YYYY-MM-DD)
`2011-08-31
`
` Application Number
`
`PTO/AlA/‘M (12-13)
`Approved for use through 04/3012017. OMB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`_
`_
`Application Data Sheet 37 CFR 1.76
`
`Attorney Docket Number
`
` Application Number
`
`209658-0001-01-US-518587
`
`Title of Invention
`
`ANTISENSE NUCLEIC ACIDS
`
`
`
`Domestic Benefithational Stage Information:
`
`This section allows for the applicant to either claim benefit under 35 U.S.C.119(e),120, 121, or 365(c) or indicate National Stage
`entry from a PCT application. Providing this information in the application data sheet constitutes the specific reference required
`by 35 U.S.C. 1 19(e) or 120, and 37 CFR 1.78.
`When referring to the current application, please leave the application number blank.
`
`Prior Application Status
`Pending
`
`Application Number
`Continuity Type
`Prior Application Number
`Filing Date (YYYY-MM-DD)
`Continuation of
`13891520
`2013-04-10
`
`
`Prior Application Status
`Expired
`
`
`
`Additional Domestic Benefit/National Stage Data may be generated within this form
`by selecting the Add button.
`
`
`Add
`
`Foreign Priority Information:
`
`This section allows for the applicant to claim priority to a foreign application. Providing this information in the application data sheet
`
`constitutes the claim for priority as required by 35 U.S.C. 119(b) and 37 CFR 1.55(d). When priority is claimed to a foreign application
`that is eligible for retrieval under the priority document exchange program (PDX) 'the information will be used by the Office to
`automatically attempt retrieval pursuant to 37 CFR 1.55(h)(1) and (2). Under the PBX program, applicant bears the ultimate
`responsibility for ensuring that a copy of the foreign application is received by the Office from the participating foreign intellectual
`property office, or a certified copy of the foreign priority application is filed, within the time period specified in 37 CFR 1.55(g)(1).
`
`2010—196032
`
`
`Filing Date (YYYY-MM-DD)
`JP
`2010—09—01
`
`Access Codei (if applicable)
`
`Additional Foreign Priority Data may be generated within this form by selecting the
`Add button.
`
`Add
`
`EFS Web 2.2.11
`
`Sarepta Exhibit 1011, Page 4 of 76
`
`

`

`PTO/AlA/‘M (12-13)
`Approved for use through 04/3012017. OMB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`
`
`Attorney Docket Number 209658-0001-01-US—518587
`
`Application Number
`
`
`Application Data Sheet 37 CFR 1.76
`
`Title of Invention
`
`ANTISENSE NUCLEIC ACIDS
`
`Statement under 37 CFR 1.55 or 1.78 for AIA (First Inventor to File) Transition
`Applications
`
`
`This application (1) claims priority to or the benefit of an application filed before March 16, 2013 and (2) also
`contains, or contained at any time, a claim to a claimed invention that has an effective filing date on or after March
`D 16, 2013.
`NOTE: By providing this statement under 37 CFR 1.55 or 1.78, this application, with a filing date on or after March
`16, 2013, will be examined under the first inventor to file provisions of the AIA.
`
`
`
`
`
`Authorization to Permit Access:
`
`Authorization to PermitAccess to the Instant Application by the Participating Offices
`
`If checked, the undersigned hereby grants the USPTO authority to provide the European Patent Office (EPO),
`the Japan Patent Office (JPO), the Korean Intellectual Property Office (KIPO), the World Intellectual Property Office (WIPO),
`and any other intellectual property offices in which a foreign application claiming priority to the instant patent application
`is filed access to the instant patent application. See 37 CFR 114(0) and (h). This box should not be checked if the applicant
`does not wish the EPO, JPO, KIPO, WIPO, or other intellectual property office in which a foreign application claiming priority
`to the instant patent application is filed to have access to the instant patent application.
`
`
`
`
`
`In accordance with 37 CFR 1.14(h)(3), access will be provided to a copy of the instant patent application with respect
`to: 1) the instant patent application—as—filed; 2) any foreign application to which the instant patent application
`claims priority under 35 U.S.C. 119(a)—(d) if a copy of the foreign application that satisfies the certified copy requirement of
`37 CFR 1.55 has been filed in the instant patent application; and 3) any US. application—as—filed from which benefit is
`sought in the instant patent application.
`
`In accordance with 37 CFR 1.14(c), access may be provided to information concerning the date 0 ffiling this Authorization.
`
`Applicant Information:
`
`Providing assignment information in this section does not substitute for compliance with any requirement of part 3 of Title 37 of CFR
`to have an assignment recorded by the Office.
`
`
`
`
`
`EFS Web 2.2.11
`
`Sarepta Exhibit 1011, Page 5 of 76
`
`

`

`PTO/AlA/‘M (12-13)
`Approved for use through 04/3012017. OMB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`Application Data Sheet 37 CFR 1.76
`
`
`
`Attorney Docket Number 209658-0001-01-US—518587
`
`Application Number
`
`ANTISENSE NUCLEIC ACIDS
`Title of Invention
`
`
`
`
`
`@ Assignee
`0 Legal Representative under 35 U.S.C. 117
`0 Joint Inventor
`
`0 Person to whom the inventor is obligated to assign.
`O Person who shows sufficient proprietary interest
`If applicant is the legal representative, indicate the authority to file the patent application, the inventor is:
`
`
`Name of the Deceased or Legally lncapacitated Inventor :
`
`
`
`If the Applicant is an Organization check here.
`
`Organization Name
`
` NIPPON SHINYAKU CO., LTD.
`
`Mailing Address Information For Applicant:
`
`
`Address 1
`14, Kisshoin Nishinosho Monguchicho, Minami-ku
`Address 2
`
`
`
`City
`Kyoto—shi, Kyoto
`StatelProvince
`
`
`
`
`1
`Applicant
`lfthe applicant is the inventor (or the remaining joint inventor or inventors under 37 CFR 1.45), this section should not be completed.
`The information to be provided in this section is the name and address of the legal representative who is the applicant under 37 CFR
`1.43; or the name and address of the assignee, person to whom the inventor is under an obligation to assign the invention, or person
`who otherwise shows sufficient proprietary interest in the matter who is the applicant under 37 CFR 1.46. If the applicant is an
`applicant under 37 CFR 1.46 (assignee, person to whom the inventor is obligated to assign, or person who otherwise shows sufficient
`proprietary interest) together with one or more joint inventors, then the joint inventor or inventors who are also the applicant should be
`identified in this section.
`
`
`
`
`
`
`JP
`Country i
`Phone Number
`
`Email Address
`
`Postal Code
`Fax Number
`
`601-8550
`
`Add
`Additional Applicant Data may be generated within this form by selecting the Add button.
`
`
`2
`Applicant
`lfthe applicant is the inventor (or the remaining joint inventor or inventors under 37 CFR 1.45), this section should not be completed.
`The information to be provided in this section is the name and address of the legal representative who is the applicant under 37 CFR
`1.43; or the name and address of the assignee, person to whom the inventor is under an obligation to assign the invention, or person
`who otherwise shows sufficient proprietary interest in the matter who is the applicant under 37 CFR 1.46. If the applicant is an
`applicant under 37 CFR 1.46 (assignee, person to whom the inventor is obligated to assign, or person who othenivise shows sufficient
`proprietary interest) together with one or more joint inventors, then the joint inventor or inventors who are also the applicant should be
`identified in this section.
`
`
`@ Assignee
`
`0 Legal Representative under 35 U.S.C. 117
`
`0 Joint Inventor
`
`0 Person to whom the inventor is obligated to assign.
`
`0 Person who shows sufficient proprietary interest
`
`
`
`
`
`If applicant is the legal representative, indicate the authority to file the patent application, the inventor is:
`
`
`@—
`
`
`
`Name of the Deceased or Legally lncapacitated Inventor :
`EFS Web 2.2.11
`
`Sarepta Exhibit 1011, Page 6 of 76
`
`

`

`PTO/AlA/‘M (12-13)
`Approved for use through 04/3012017. OMB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`Application Data Sheet 37 CFR 1.76
`
`
`
`Attorney Docket Number 209658-0001-01-US—518587
`
`Application Number
`
`ANTISENSE NUCLEIC ACIDS
`Title of Invention
`
`
`
`If the Applicant is an Organization check here.
`
`NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
`organizatim Name
`
`
`Mailing Address Information For Applicant:
`
` Address 1 1-1, Ogawahigashicho 4-ch0me
`
`Address 2
`
`
`
`
`
`City
`Kodaira—shi, Tokyo
`StatelProvince
`
`
`Country i
`JP
`Postal Code
`187-8551
`Phone Number
`Fax Number
`
`
`
`
`Email Address
`
`Additional Applicant Data may be generated within this form by selecting the Add button.
`
`Add
`
`Assignee Information including Non-Applicant Assignee Information:
`
`Providing assignment information in this section does not subsitute for compliance with any requirement of part 3 of Title 37 of CFR to
`have an assignment recorded by the Office.
`
`
`
`Assignee 1
`Complete this section if assignee information, including non-applicant assignee information, is desired to be included on the patent
`application publication . An assignee-applicant identified in the "Applicant Information" section will appear on the patent application
`publication as an applicant. For an assignee-applicant, complete this section only if identification as an assignee is also desired on the
`patent application publication.
`
`
`If the Assignee or Non-Applicant Assignee is an Organization check here.
`
`organizatm” Name
`NIPPON SHINYAKU 00., LTD.
`
`
`Mailing Address Information For Assignee including Non-Applicant Assignee:
`
`
`Address 1
`
`Address 2
`
`14, Kisshoin Nishinosho Monguchicho, Minami—ku
`
`
`City
`Kyoto—shi, Kyoto
`StatelProvince
`
`
`
`
`
`
`
`
`
`Country i
`
`JP
`
`Phone Number
`
`Email Address
`
`Postal Code
`
`Fax Number
`
`601-8550
`
`Additional Assignee or Non-Applicant Assignee Data may be generated within this form by
`selecting the Add button.
`
`Add
`
`EFS Web 2.2.11
`
`Sarepta Exhibit 1011, Page 7 of 76
`
`

`

`PTO/AlA/‘M (12—13)
`Approved for use through 04/3012017. OMB 0651-0032
`US Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`Application Data Sheet 37 CFR 1.76
`
`
`
`Attorney Docket Number 209658-0001-01-US-518587
`
`Application Number
`
`ANTISENSE NUCLEIC ACIDS
`Title of Invention
`
`
`
`Assignee
`
`2
`
`Complete this section if assignee information, including non—applicant assignee information, is desired to be included on the patent
`application publication . An assignee—applicant identified in the "Applicant Information" section will appear on the patent application
`publication as an applicant. For an assignee—applicant, complete this section only if identification as an assignee is also desired on the
`patent application publication.
`
`Remove
`
`
`If the Assignee or Non-Applicant Assignee is an Organization check here.
`
`NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
`organ'zam” Name
`
`
`Mailing Address Information For Assignee including Non-Applicant Assignee:
`
`Address 1
`
`Address 2
`
`1—1, Ogawahigashicho 4—chome
`
`
`
`
`‘
`
` Country i
`
`State/province —
`Kodaira-sm.Tokyo
`Postal Code
`187-8551
`
`
`Phone Number
`Fax Number
`
`
` Email Address
`
`
`Additional Assignee or Non-Applicant Assignee Data may be generated within this form by
`selecting the Add button.
`
`
`Add
`
`
`Signature:
`
`NOTE: This form must be signed in accordance with 37 CFR 1.33. See 37 CFR 1.4 for signature requirements and
`certifications.
`
`
`
`
`
`thengyu Feng/
`
`Signature First Name
`
`Date (YWY-MM-DD)
`
`2015—02—06
`
`Additional Signature may be generated within this form by selecting the Add button.
`
`This collection of information is required by 37 CFR 1.76. The information is required to obtain or retain a benefit by the public which
`is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This
`collection is estimated to take 23 minutes to complete, including gathering, preparing, and submitting the completed application data
`sheet form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to
`complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and
`Trademark Office, US. DepaItment of Commerce, PO. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR
`COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
`
`EFS Web 2.2.11
`
`Sarepta Exhibit 1011, Page 8 of 76
`
`

`

`Privacy Act Statement
`
`
`
`
`
`The Privacy Act of 1974 (PL 93—579) requires that you be given certain information in connection with your submission of the attached form related to
`a patent application or patent. Accordingly, pursuant to the requirements ofthe Act, please be advised that:
`(1) the general authority for the collection
`of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is
`used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent.
`If you do not
`furnish the requested information, the U.S. Patent and Trademark Office may not be able to process andlor examine your submission, which may
`result in termination of proceedings or abandonment of the application or expiration ofthe patent.
`
`The information provided by you in this form will be subject to the following routine uses:
`
`1.
`
`The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552)
`and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine
`whether the Freedom of Information Act requires disclosure of these records.
`
`A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or
`administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
`
`3.
`
`A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an
`individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of
`the record.
`
`A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in
`order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as
`amended, pursuant to 5 U.S.C. 552a(m).
`
`A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed,
`as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent C o o p eration Treaty.
`
`A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security
`review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
`
`A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hislher designee,
`during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records
`management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the
`GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such
`disclosure shall not be used to make determinations about individuals.
`
`A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuan
`to 35 U.S.C. 122(b) or issuance ofa patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37
`CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were
`terminated and which application is referenced by either a published application, an application open to public inspections or an issued
`patent.
`
`A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the
`USPTO becomes aware of a violation or potential violation of law or regulation.
`
`EFS Web 2.2.11
`
`Sarepta Exhibit 1011, Page 9 of 76
`
`
`
`

`

`Under the Pape:w5:k Reductinn .5510? 1995, no parscns are ram;
`
`555115551511 13525 $115513? QFR 1 ”E5
`“w“KK5‘KKkukk”Akkkukkkkwm...“KN“____\\\\\\\\\\fifififififi\fimu.fl“...
`
`r wmwm‘mm,
`Approved far use through (1413012017. 0MB (16515032
`1.18 Paieni and Trademaik Office; as DEPARTMENT OF COMMERCE
`
`
`:5 tr: regpund 1-3 3 coiieciion ai‘ irir‘c-r
`iien usiEess it contains a 115' {MB SWEEP-Di 51L her.
`
`
`Niamey DQCRE‘I Number
`rrrrrrrrrrrrrrrr
`Appiscahon Number
`
`255558—0061—01wU5-518587
`
`
`
`
`
`
`
`
`ANTiSENiSE NUCLEIC ACEDS
`
`
`T1115 of inventien
`1W~W.....M
`
`
`
`p
`‘ The appiicaiian data sheet is part of
`. nprovisiena! apgiicaiion fer which 11 is being submitted. The faiicwing form contains 1113
`bibiisgraphic 5515 arranged in a format specified by the United States Pateni and Ta‘ademark 011155. as outiined in 37 CFR 1.?5.
`This document may be 135515315195 eiect-onicaiiy and submittssd to the Office in eiecirtsnic format using 1115 Eiectmnic Fiiing System (EFS‘) 5r 11:5
`
`niacurnei:° may 1355111115an5 smiuded in apaper111561 apgiicauon
`
`1: P51115113 m exit of the appiicatien 35355151551515 this Age-phi: 11531 Data Sheet may 1511 under 5 Secrecy 05:15: 5555115111 151
`
`37 C552 5 2 {135555 fliers oniy Apphaatmms 11131fat}11.555} 55:35:51 (235151 ma" 115113511155 eiecimnicaiiy 1
`‘
`
`1115511151" 1515151511511:
`1 1555mm“
`1
`Legai N5m5
`
`1
`j
`
`
`
`
`Famiiy Nam5 WW $511151
`
`13155311 Given Name
`5 11515515155255
`
`
`
`a US Miiiflarv Service
`"@"méiiiifiié’fieéidency
`Q At:
` Cwntry 51 12551551155 ‘
`
`V Naifling 5551:5355 51 1315551015
`
`
`Addnms in1WROC11‘1’1432:RUVIQ112531’% 551mm1~Lhome
`
`E 51551555 2
`
`
`
`Siaieivamw ‘
`City M1Tsukub5shiNaraki
`
`305550E“
`(355311.
`1....
`JP
`VP5515:M35515
`"Evy.-
`.......
`....u............
`__________
`
`
`1Famiiy N5m5
`‘
`_
`
`
`
`
`
`1
`
`
`invents)?
`
`
`2
`
`
`
`
`“va“ W w.m
`
`1305511751 1“JP
`i
`
`
`
`$1515IP5551555
`
`
`
`
`
`"750551(2555
`
`I“
`
`= 115555153“ ‘ 3
`1.5551 Némé
`
`ESQ h‘i-Mh '3 '3 4 vi
`
`Sarepta Exhibit 1011, Page 10 of 76
`
`

`

`Undey the
`
`
`
`‘.......................................
`waikszmiftéfm A0107 1995 :12: p2:(sums are required to raw-mats '5
`
`aasssauoemmuUS—smsw
`mm m :AttcsrneyDockémumber
`3
`I Angiaatim Data Shea: 3“? CFR ‘i 2%WM»»»»»»»»»»»»»»»»»»»»»»»»»»»»»»»»»»»»»»»»»»»»»»»»»»»»»»»»»»»»»»»»»»»»»»»»»»»»»»»»»»»»»»»»»»»»»»»»»»»»»»»»»»»»»»»»»»»
`EAppiicati9n Number
`14’835. 504
`
`r luyrurv m [unto]
`App.{wed for us:Eh:cuqh 04'301201?.OMB 06.51.0032
`U S. Pater-fi and Trademark. Office; US. DEPART:AENT OF CQMMERCE
`0‘
`on c? iniormatior: uniess
`a Si
`‘c‘ OMB contra! number
`
`
`
`
`
`EwpmtaiGame
`
`é
`Hmentar
`Legai Name
`
`
`
`
`
`
`
`
`
`
`
`
`do Nationai Center 0‘? Neuroiogy and Psyc Hairy
`
`Enter either Custnmw Numbar {32' wmpieie the Cermsmndeme information semen bgiew H
`Fm furfimr isfiarmafiiun mm 3? {EFR 1 fifigaE
`
`
`L] An Addressas being pmwsied far the wrmspendence Enfarmatian 6f Eh§$ agpiicafian
`
`finstamer Numhar ..
`
`{355534
`
`
`
`
`Emmi Afiafiress
`“““
`
`
`EEQ Mink ’3 '3 4‘1
`
`Sarepta Exhibit 1011, Page 11 of 76
`
`

`

`r IU!!'!!NI".1‘!L"EJII
`Approved?BF useihrcugh 04l§m20170ME 065E(3032
` v Acicf 1995, nu pawns are required it:- rns E w “
`‘ coiiac‘iian o .r:iorrriatic-ri ur:ies
`‘OMB conirui nunibes.
`US. Paieni a-vi Trademark Cir":ice; 1} 8 DEPARTMENT OF CQMMERCE
`
`~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~w
`
`Under the Paperwork Red
`
`
`
`Tiiie Qi invnriiinn
`
`ANTESENSE NUCLEEC ACEDS
`
`.1 11111;,
`$uisjnet Matter
`Ema: Nnmber 9E firawing Sheets(1Eany)
`Fiimg Egg EEeEnmnm.
`Oniy compieie this section when fiiing an appiicaiion by refereriize undar 35 USE; 111(c) and 37 CFR 1157123?“ {20 mt compiete this sectien if
`appiication papers inciuding a specificatinn and any drawings am being filed, Any demestic benefit or foreign priority infarmation must be
`provided in the appropriate sectionis) beiaw (Le, “Dcmestic BenefitiNationai Stage infurmaiion" and "Foreign Prim‘ity information").
`
`§ 19
`
`ESuggested Figure mi Puniicaiieniiiany) I
`
`
`4
`
`
`
`
`
`
`
`
`
`
`
`
`Far the purposes of a fiiing date under 37 CPR 1.53%), the descriptinn and any drawings of this present appiication are repiaced by this
`reference to the previcusiy flied application, subject in conditions and requirements 0f 37 CFR 157(3).
`«WWWWWW wwwmwwwwmsssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssi
`Appiicaiinn number ofti'ie previousiy
`Fiiing date (YYYY-MM'DD)
`inteiiecmai Pmperty Auihizrity 0r Country
`fiied apniicaiion
`
`
`
`Puisimn‘imn inEnEmnEien:
`":1 RequestEariy Pubiication (Fee requrred at timeGiReque3137 CFR 1.219}
`
`
`
`E“:
`
`i hereby risque-5i that the attached appiicaiion mi be pubiished under
`finqnnst Ni}? '10 Pukiini’i.
`35 13.8.6. 122(k)} and certify tirai the inventien disainsed in the aitacheci appiicaiion has rant and wiii mi ion the
`subject of an appiicaiion flied in 3min rccuntry, or under a muiiiiaierai internaiinnai agreement, that requires
`.
`' Emsshssss‘sssvsss«sss«sss«sssWsVVmssss«sss«WsVWsss«sss««sssssssssmssssssssm.hmhn,n.«ssssmsssssssssssssmsssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssi
`pubiicaiion a1 eighteen menihs after fiiing.
`
`Reps‘eseniaiiva inEfiEmaEinn:
`
`Representative infm‘maiion simuin‘ be provided far 311 practitioners having a pnwer of aitorney in the appiication. Providing
`this infnrrnaiion in the Appiicaiion [Data Sheet does not constitute a power 01 attorney in the appiication {see 37 CFR 1.32).
`Either enter Cusitsrner Number 0r compieie the Representaiive Name section beiow.
`if both sections are compieied ihe customer
`Number wiii be used in: the Representative infnirnaiion during processing.
`
`‘ P
`
`l
`@ Cusinmer Number 1L; LES Patent Piaciiiinner 0 Limited Recognition (37 CFR 11i3)
`iease 391861 One:
`:“WWWn‘nn‘nn,nm“.......mmmmmnmw:
`055E394
`Custamer Numbesr
`i.kukkkuVs~wVsw2WWW...s________unuuwwummw 2kkkuk____kkw“22‘222s:siss:s"issi"2sssukk2wmW222Msmmw22sississ:sssas"is"suskkw22kukkkukkkukW...222‘ssss:siwam‘wywyww.mmmm....wVV-V-V-V-V-V-V-V-V-V-V-V-V-V-v-V-vW..-.-.-.-.-.-.waw:
`
`can: \IUAM r: a 1 1
`
`Sarepta Exhibit 1011, Page 12 of 76
`
`

`

`r iUlHll‘v I“? \iL-Id!‘
`Approved for use Waugh-11413110011. 0M8 11651503?
`Li. S Patent andTrademark affine; USDEPARTMENT OF COMMERCE
`
`
`Under 11191121119111.11er Reduciicr‘. {11:10.1 13135 110 persons aree.
`'
`1110 respond in a miliecirrm :11 infnrrrahcrr 1m
`Attorney Dacha? Number ‘
`203111.1800111(1111361858?
`EAppAmAAA 1:11.113 3111131 3'? 131:1111% ~~wwmwmmmm -mmmmmmAAAAAAAAAAAAAAAAAAAAAAAAAA
`
`
`,
`
`Appiicaiion Number
`
`1411615 $114
`
`11119011111161111131‘1
`
`ANTESENSE NUCLEK)
`
`£11213
`
`DcmAA‘iin Senafitihiatianai Shana inmrmatinn:
`
`
`
`r1‘111‘3::5“£115'11-‘311‘5151‘51‘1231‘111:3211-1511213
`. 10 e111191 {131-m benefit undérBS . L. 1 19(8), 128.121,or365111 or indicate Nan’onai Stagé
`Eentry from a PCT applicatian. Providing this infermationin the application data sheet canstitutes the specific reference requirEed
`Eby 35 U.S.C. 1111161211120 and 37'CPR178.
`EWhen referring tn the current appiicatien piease Eeave the appiication number biank.
`
`P1101 Appiicaiian Status
`
`Pending
`
`Addrtionai Domestic BenefstiNatmnai StageDatamay his generated within this 15% '
`iEby seiecting the A1111 button.
`
`TEhis section allows far the appiicant 10 ciaim priority 10 a foreign appiicatign Providing this informatirm in the applicafiion da‘ia sheet
`Econstitutesz {he 131511111 for prioriiy as requirsd by 35 U3.6.1 19(b) and 37 CF12 155M). When priorityis ciaimsd in a foreign appiication :
`E'ihaiis eiigihie far retrievai under the primiiy dccnrneni exchange program (PBX) the infermatian wiii be used by the Office 10
`Eautomaticaiiy attempt retriavai pursuant tr) 3? CFR 1.5501101 and (21. Unde. the PBX pragzam. appiicani bears the iriiimaia
`Eresponsibiiiiy for ensuring that a copy 011116 foreign application is received by the Office 119111 the participating foreign intellectual
`Eproperty affice, or a certified copy (11 the foreign priority appiicaiion is 111911, wiihin She iime period specified in 37 CFR 1.5519(1).
`
`
`
`Appimahon Number
`Country
`E Filing Date {1’31’1’MM.DD)“
`i\ccess(Ends‘(ifappircabie)
`..-.
`.....
`,,,,,,,
`
`JP
`E 20101953032
`E201009()1
`Add111::1%113F111§K13118111§135g‘$111‘Efié‘fignue‘ééiéfiuifii11E1%k11;}1Ekk151113}‘gals-“131.11Eé;‘111is}kk“WNWNWWW“““““““““““““““‘ “““““E
`E Add 131111011.
`
`i 1
`
`
`
`can ”Huh ’2 ’5 4 4
`
`Sarepta Exhibit 1011, Page 13 of 76
`
`

`

`Under the Paperwork Reduction Act of 1395. he persons a